Imperial College London

ProfessorCharlotteBevan

Faculty of MedicineDepartment of Surgery & Cancer

Professor of Cancer Biology
 
 
 
//

Contact

 

charlotte.bevan Website

 
 
//

Assistant

 

Mrs Suzy Ford +44 (0)20 7594 2135

 
//

Location

 

139ICTEM buildingHammersmith Campus

//

Summary

 

Summary

Qualifications and Employment History

  • BA in Natural Sciences (Part II Genetics), University of Cambridge, 1992.
  • Postdoctoral work at London Research Institute, Cancer Research UK, 1996-1999.
  • Joined Imperial College in 1999 as Lecturer and head of the Androgen Signalling Group in the Department of Oncology.
  • Current position: Professor of Cancer Biology, Non-Clinical Head of Prostate Cancer Research in Department of Surgery & Cancer.

Research Interests

  • Mechanisms of androgen receptor action. 
  • Androgen signalling in development and disease.
  • Nuclear receptor coactivators and corepressors.
  • Mechanisms of therapy resistance in hormone-dependent cancers.
  • Novel therapies for prostate cancer.
  • Discovery and validation of biomarkers for prostate cancer.
  • Role of microRNAs in androgen signalling.

Teaching Activities

UNDERGRADUATE TEACHING

  • BSc Medical Biosciences - Module Lead for Cancer Biology
  • Lecturer and project supervisor for MBBS BSc year

Postgraduate Taught Courses

  • MSc Molecular Medicine
  • MRes Cancer Biology
  • MSc Human Reproduction

Postgraduate Supervision

  • PhD project supervisor
  • Masters project supervisor for MRes Cancer Biology, MSc Human Reproduction, MRes Biomedical Sciences, MSc Molecular Medicine

Other College roles

Member of the Imperial College 3Rs committee

Member of the Postgraduate Education Committee for Surgery & Cancer

Member of the Academic Opportunities Committee for Surgery & Cancer

Member of the Imperial Student Withdrawals/Appeal panel

 

Collaborators and External Committees

Please see "Research" tab above

Selected Publications

Journal Articles

Fletcher CE, Godfrey JD, Shibakawa A, et al., 2017, A novel role for GSK3 beta as a modulator of Drosha microprocessor activity and MicroRNA biogenesis, Nucleic Acids Research, Vol:45, ISSN:0305-1048, Pages:2809-2828

Leach DA, Powell SM, Bevan CL, 2016, New roles for nuclear receptors in prostate cancer, Endocrine-related Cancer, Vol:23, ISSN:1351-0088, Pages:T85-T108

Bevan CL, 2016, WOMEN IN CANCER PROFILE: A gender agenda?, Endocr Relat Cancer, Vol:23, Pages:P5-P8

Metcalf GAD, Shibakawa A, Patel H, et al., 2016, Amplification-Free Detection of Circulating microRNA Biomarkers from Body Fluids Based on Fluorogenic Oligonucleotide-Templated Reaction between Engineered Peptide Nucleic Acid Probes: Application to Prostate Cancer Diagnosis, Analytical Chemistry, Vol:88, ISSN:0003-2700, Pages:8091-8098

Brooke GN, Powell SM, Lavery DN, et al., 2014, Engineered repressors are potent inhibitors of androgen receptor activity, Oncotarget, Vol:5, ISSN:1949-2553, Pages:959-969

Dart DA, Waxman J, Aboagye EO, et al., 2013, Visualising Androgen Receptor Activity in Male and Female Mice, PLOS One, Vol:8, ISSN:1932-6203

Sita-Lumsden A, Dart DA, Waxman J, et al., 2013, Circulating microRNAs as potential new biomarkers for prostate cancer, British Journal of Cancer, Vol:108, ISSN:0007-0920, Pages:1925-1930

Fletcher CE, Dart DA, Sita-Lumsden A, et al., 2012, Androgen-regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer, Human Molecular Genetics, Vol:21, ISSN:0964-6906, Pages:3112-3127

Brooke GN, Culley RL, Dart DA, et al., 2011, FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth, Cancer Research, Vol:71, ISSN:0008-5472, Pages:914-924

Brooke GN, Parker MG, Bevan CL, 2008, Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression, Oncogene, Vol:27, ISSN:0950-9232, Pages:2941-2950

Gamble SC, Chotai D, Odontiadis M, et al., 2007, Prohibitin, a protein downregulated by androgens, represses androgen receptor activity, Oncogene, Vol:26, ISSN:0950-9232, Pages:1757-1768

More Publications